Across TCGA pan-cancer cohorts, PRELID2 Mutation is linked to patient survival in 2 of 34 cancer types, making it a survival-associated PRELID2 data layer compared with 24 for mass-spec protein.

The strongest signal is observed in bladder urothelial carcinoma (BLCA), where higher PRELID2 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated PRELID2 expression acts as an unfavorable survival marker.

BLCA and LUSC are the cancer types where PRELID2 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
BLCA	OS	Median	All	0.191	0.711	<.001	45	view →
LUSC	OS	Median	All	0.286	0.676	.032	9	view →

Pink = unfavorable, green = favorable. Showing the 2 strongest of 2 lineages.

Exploration

Same gene, other analysis: PRELID2 tumor-vs-normal RNA expression · all PRELID2 data types